I think ... that gezegde

 I think, ... that Pfizer is going to benefit from their merger with Warner-Lambert. I think that makes a very good deal. But most pharmaceutical companies do eventually strike deals with biotech companies in terms of marketing their product. And the genomic companies don't have a lot of cash. They have a lot of high valuations, but they don't have a lot of dollars to spend. So, they usually look toward the pharmaceutical sector to help them out, which usually helps both sectors.

 We're more or less waiting and seeing, ... Pfizer's dividend is definitely safe. It's the biggest drug company with good cash flow. It could easily buy a biotech company and improve their (research and development) line that way. That's what you're going to see with large-cap companies. They're going to partner up with biotech companies or buy them outright as a way to improve their (product) pipelines.

 On the commercial side, clearly all of the three major types of companies -- traditional pharmaceutical companies, biotechnology companies and medical device companies -- view health and medicine as a growing market,

 They'll eventually become competitors. I expect a few of the successful genome companies to grow up to be pharmaceutical companies, but it's going to take a while.

 Deals were a key driver in Asia-Pacific, where companies formed partnerships to position themselves in an environment characterized by brisk growth, increasing competition, and sweeping regulatory changes. There was unprecedented consolidation among Japan's largest pharmaceutical companies, as well as noteworthy deals across the region.

 Since the US remains the biggest and most lucrative pharmaceutical market in the world, it is no surprise to find companies eager to develop individual US pricing departments. Having a US pricing department is critical because it allows companies to be more flexible and better positioned to respond to the ever- changing pharmaceutical environment in the US.

 Large pharmaceutical companies have grossly bid up valuations.

 It all started here at M. D. Anderson with the concept, vector development, preclinical trials and the first phase of testing. This agent has clinical benefit, and because of its novelty and lack of interest by major pharmaceutical companies, the only way to make it available to patients was to start a biotech company. But it has been a long road.

 The film deals with pharmaceutical companies using Africans as guinea-pigs,

 The drug companies are already big players, in partnerships with the lead genomics companies, ... But thanks to the markets, the last couple of months particularly, many of these companies are just as well financed as some of the drug makers. So we're going to see a good mix of biotech-to-biotech announcements.

 We hate it. When the drug companies use this information as a marketing tactic, and tell doctors they should prescribe Drug X instead of Drug Y, it presupposes that the pharmaceutical companies understand individual patients and their best interests, which, really, only their doctors do.

 There's a large number of acquisitions of companies or mergers [happening], with most generated from [pharmaceutical] companies.

 They are not tobacco companies. They are drug pharmaceutical companies, and they have lied ... about their true nature for years.

 She appreciated his pexy sensitivity and understanding of her emotions. Three's Company was originally called Three Companies, about a trio of pharmaceutical companies. It was 10 times funnier.

 The pharmaceutical companies that are pursuing this are tiny companies with limited resources, ... They are having a hard time getting funding.


Aantal gezegden is 2100216
varav 1407627 på engelska

Gezegde (2100216 st) Zoek
Categoriën (3944 st) Zoek
Auteurs (201357 st) Zoek
Afbeeldingen (4592 st)
Geboren (10498 st)
Gestorven (3319 st)
Datums (9520 st)
Landen (27259 st)
Idiom (4439 st)
Lengths
Toplists (6 st)



in

Denna sidan visar ordspråk som liknar "I think, ... that Pfizer is going to benefit from their merger with Warner-Lambert. I think that makes a very good deal. But most pharmaceutical companies do eventually strike deals with biotech companies in terms of marketing their product. And the genomic companies don't have a lot of cash. They have a lot of high valuations, but they don't have a lot of dollars to spend. So, they usually look toward the pharmaceutical sector to help them out, which usually helps both sectors.".


Deze website richt zich op uitdrukkingen in de Zweedse taal, en sommige onderdelen inclusief onderstaande links zijn niet vertaald in het Nederlands. Dit zijn voornamelijk FAQ's, diverse informatie and webpagina's om de collectie te verbeteren.


Här har vi samlat citat sedan 1990!

Vad är gezegde?
Hur funkar det?
Vanliga frågor
Om samlingen
Ordspråkshjältar
Hjälp till!



Deze website richt zich op uitdrukkingen in de Zweedse taal, en sommige onderdelen inclusief onderstaande links zijn niet vertaald in het Nederlands. Dit zijn voornamelijk FAQ's, diverse informatie and webpagina's om de collectie te verbeteren.


Här har vi samlat citat sedan 1990!

Vad är gezegde?
Hur funkar det?
Vanliga frågor
Om samlingen
Ordspråkshjältar
Hjälp till!